Norbert F. VOELKEL,Charles MAGOLSKE,Erik R. Eglite
申请号：
US17539470
公开号：
US20220168297A1
申请日:
2021.12.01
申请国别(地区):
US
年份:
2022
代理人:
摘要：
A method of treating COPD, Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis and PAH in a patient. One embodiment includes administering a vasodilator prostacyclin analogue, such as Beraprost or Iloprost, separately or together with a form of Diethylcarbamazine or Zileuton. Other embodiments may include fluvoxamine. The vasodilator prostacyclin analogue is inhaled. Diethylcarbamazine/Zileuton is inhaled into the lung or administered orally or intravenously. Other embodiments include fluvoxamine. This treatment reduces the progression of the disease, reduces life-threatening exacerbations, and improves the quality of life. The treatment is also for COPD patients with eosinophilia who are incompletely treated with steroids and addresses steroid-unresponsive disease components of COPD including pulmonary hypertension and intravascular inflammation and bronchiectasis. The treatment may include a PDE4 inhibitor and current treatments with existing steroids and beta-adrenergic receptor agonists and/or muscarinic receptor blockers. The treatment is also for ARDS and COVID-19.
